Form 4: Terns Pharmaceuticals Director Receives Stock Options in Lieu of Cash Retainer

David A. Fellows, a director at Terns Pharmaceuticals, received stock options in lieu of a $70,000 cash retainer for 2025.

Summary

• David A. Fellows, a director of Terns Pharmaceuticals, received 18,650 stock options on February 1, 2025.
• These options were granted in place of his $70,000 cash retainer for the year 2025.
• The options have an exercise price of $4.46 per share.
• The options vest monthly starting January 1, 2025, with full vesting by January 1, 2026.
• The options expire on January 31, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally positive as it aligns director interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The director's decision to take stock options instead of cash may indicate confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Risks

• The value of the stock options is dependent on the future performance of Terns Pharmaceuticals' stock price.
• If the stock price does not increase above the exercise price, the options may not be valuable.

Industry Context

This type of compensation is common for directors of publicly traded companies, aligning their interests with shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice in the pharmaceutical industry, often used to incentivize long-term value creation.
• The vesting schedule of these options is typical, with monthly vesting over a year to ensure continued engagement.
• The exercise price of $4.46 is a key factor in determining the value of the options, and will be compared to the market price of TERN stock over time.

Stakeholder Impact

• Shareholders may view this as a positive sign, as it aligns the director's interests with the company's long-term success.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, director compensation, insider trading, Terns Pharmaceuticals, equity, vesting